Evidence map›Paper›PMID 32380703›Full record

ReviewCancers2020

Acquired Resistance to Immune Checkpoint Blockade Therapies.

Xianda Zhao, Dechen Wangmo, Matthew Robertson, Subbaya Subramanian

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Xianda ZhaoDepartment of Surgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0002-7926-4900
Dechen WangmoDepartment of Surgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Matthew RobertsonDepartment of Surgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Subbaya SubramanianDepartment of Surgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.ORCID 0000-0002-2544-480X
University of Minnesota Medical Center · USUniversity of Minnesota · US

Funding

Atypical Chemokine Receptor 4 (ACKR4) in Anti-tumor Immunity in colorectal cancerR03CA219129 · NCI · UNIVERSITY OF MINNESOTA · PI SUBRAMANIAN, SUBBAYA · 2017 to 2018
$147k
NIH HHS R03CA219129
6 · The paper itself

Abstract

Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinical investigation in mouse models of cancer provide insight into how tumors evade ICBT after an initial response to treatment. Here, we summarize our current knowledge on the development of acquired ICBT resistance, by examining the mechanisms related to tumor-intrinsic properties, T-cell function, and tumor-immune cell interactions. We discuss current and future management of ICBT resistance, and consider crucial questions remaining in this field of acquired resistance to immune checkpoint blockade therapies.

Indexed as

acquired resistanceCTLA-4immune checkpoint blockadeimmune responsePD-1T cellstumor immunology

Identifiers

PMID32380703
PMCPMC7280955
OpenAlexW3021742355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.